Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.5070
Abstract: 5070Background: Prior response to A or E does not predict sensitivity to E following A or A following E. The detection of AR-V7 predicts insensitivity to either drug, but identifies only a portion ... read more here.
Keywords: mcrpc patients; outcomes mcrpc; ctc subtype; baseline ctc ... See more keywords
Early changes in PSA and association with outcomes in mCRPC patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5063
Abstract: 5063Background: Declines in prostate specific antigen (PSA) levels at 12-weeks are currently used to evaluate treatments response in metastatic castration resistant prostate cancer (mCRPC). Early P... read more here.
Keywords: association outcomes; outcomes mcrpc; mcrpc patients; psa association ... See more keywords